# Module 14B: CRISPR-Based Epigenome Editing for Neuroregeneration - Evidence Consolidation and Consensus Readiness

## Overview

This tracker converts the saturated Module 14A first-pass corpus into atomic observations, separated author claims, evidence links, boundary conditions, and consensus-ready statements for CRISPR-based epigenome editing in neuroregeneration. It keeps dCas9-mediated gene regulation separate from permanent genome editing and preserves tool, effector, target gene, cell population, delivery, chromatin mechanism, endpoint, and translation boundaries.

**Input corpus**: Module 14A first-pass corpus, 16 source rows and 16 experiment-level rows.

**Module 14 first-pass curation freeze**: 2026-07-21. Status: CONSENSUS-READY FIRST PASS.

## Evidence Topic Map

| Topic ID | Consensus-Ready Topic | Primary Sources | Evidence Need | Status |
|---|---|---|---|---|
| M14B-T001 | CRISPR epigenome editing can repress regeneration-inhibitory loci without nuclease editing | M14A-P001, M14A-P009, M14A-P010 | Preserve target, effector, chromatin mark, and regeneration endpoint boundaries | CONSENSUS-READY FIRST PASS |
| M14B-T002 | Neuronal CRISPRa/i platforms enable tunable endogenous gene regulation | M14A-P002, M14A-P004, M14A-P005, M14A-P014 | Preserve neuronal subtype, vector, promoter, guide, and in vivo/in vitro boundaries | CONSENSUS-READY FIRST PASS |
| M14B-T003 | Chromatin-effector choice determines whether editing is activation, repression, methylation, demethylation, or acetylation | M14A-P003, M14A-P011, M14A-P012, M14A-P013 | Preserve effector domain, durability, reversibility, and locus specificity | CONSENSUS-READY FIRST PASS |
| M14B-T004 | SCI and CNS injury epigenetic landscapes define candidate regulatory nodes | M14A-P006, M14A-P007, M14A-P008 | Preserve injury timing, enhancer/promoter, cell-state, and regeneration endpoint boundaries | CONSENSUS-READY FIRST PASS |
| M14B-T005 | Injury-responsive enhancers may provide cell-state-specific delivery or expression logic | M14A-P007, M14A-P008 | Preserve enhancer specificity and target cell-state boundaries | CONSENSUS-READY FIRST PASS |
| M14B-T006 | Neuroregeneration target discovery supports but does not equal epigenome-editing efficacy | M14A-P009, M14A-P010 | Separate target nomination from dCas9-based regulatory validation | CONSENSUS-READY FIRST PASS |
| M14B-T007 | Delivery and safety constraints are central for CNS translation | M14A-P003, M14A-P014, M14A-P015, M14A-P016 | Preserve vector capacity, immune/off-target, durability, and reversibility boundaries | CONSENSUS-READY FIRST PASS |
| M14B-T008 | CRISPR epigenome editing should be treated as a programmable validation and repair-modulation platform | M14A-P001-P016 | Link target, cell type, chromatin mechanism, model, and endpoint before therapeutic claims | CONSENSUS-READY FIRST PASS |

## Pass 4A: Atomic Observations Extracted

| Observation ID | Topic ID | Paper ID | Experiment ID | Figure Ref | Evidence Type | Outcome Type | Observation Value | Normalized Value | Unit | Quantitative | Statistics Reported | Source Section | Extraction Confidence | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M14B-O001 | M14B-T001 | M14A-P001 | M14A-P001-E001 | Abstract/source page | CRISPR epigenome editing evidence | PTEN repression and neurite outgrowth | dCas9-KRAB repressed PTEN, induced promoter histone methylation/deacetylation, outperformed shRNA, and enhanced PC-12 neurite outgrowth. | dCas9-KRAB PTEN repression enhances neurite outgrowth | qualitative | NO | Source-page first pass; exact statistics not extracted | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Direct regeneration-relevant CRISPRi anchor. |
| M14B-O002 | M14B-T002 | M14A-P002 | M14A-P002-E001 | Full-text PMC | neuronal CRISPRa platform evidence | endogenous gene activation | Neuron-optimized CRISPRa produced robust, tunable, multiplexed, and promoter-selective gene activation in neurons and in vivo CNS structures. | neuronal CRISPRa enables tunable endogenous activation | qualitative | NO | Full-text first pass; exact effect sizes not materialized here | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Tool-platform anchor for neuronal gene activation. |
| M14B-O003 | M14B-T003 | M14A-P003 | M14A-P003-E001 | Abstract/source page | neuroepigenome editing evidence | chromatin-effector toolkit | Review maps locus-specific neuroepigenome editing tools and emphasizes chromatin-effector boundaries in vivo. | neuroepigenome editing toolkit boundary | qualitative | NO | Review/source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Tool-class boundary row. |
| M14B-O004 | M14B-T002 | M14A-P004 | M14A-P004-E001 | Full-text PMC | CNS CRISPR review evidence | local chromatin regulation | CNS CRISPR review identifies dCas9-based chromatin modification as a modular way to interrogate neuronal gene regulation. | dCas9 enables local chromatin regulation in CNS | qualitative | NO | Review-level evidence | Module 14A tracker / source-page, full-text PMC, or review metadata | high | CNS tool context. |
| M14B-O005 | M14B-T003 | M14A-P005 | M14A-P005-E001 | Full-text PMC | neurobiology CRISPR/chromatin evidence | enhancer and epigenome manipulation | Review separates enhancer editing, CRISPRa/i, and epigenome manipulation as distinct neurobiology applications. | enhancer editing and epigenome manipulation are distinct tool uses | qualitative | NO | Review-level evidence | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Prevents tool-class collapse. |
| M14B-O006 | M14B-T004 | M14A-P006 | M14A-P006-E001 | Full-text PMC | SCI epigenetic context evidence | regeneration and secondary injury | SCI review links post-injury epigenetic landmarks to regeneration and secondary injury, supporting target selection for epigenome editing. | SCI epigenetic landmarks inform target selection | qualitative | NO | Review-level evidence | Module 14A tracker / source-page, full-text PMC, or review metadata | high | SCI context anchor. |
| M14B-O007 | M14B-T004 | M14A-P007 | M14A-P007-E001 | Full-text PMC | injury enhancer evidence | regeneration-associated enhancer regulation | Injured cortical neuron study identifies enhancer-level epigenetic regulation of WNT3A during regeneration. | WNT3A enhancer regulation in injured neurons | qualitative | NO | Full-text first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Enhancer target candidate row. |
| M14B-O008 | M14B-T005 | M14A-P008 | M14A-P008-E001 | Abstract/source page | CNS injury enhancer evidence | cell-state-specific targeting | Injury-responsive enhancers in mouse spinal cord injury retain cell-type specificity and can target reactive astrocytes across CNS using gene-delivery vectors. | injury enhancers target reactive astrocyte states | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | SCI enhancer targeting boundary. |
| M14B-O009 | M14B-T006 | M14A-P009 | M14A-P009-E001 | Abstract/source page | regeneration target-discovery evidence | axon regeneration target nomination | Optic nerve screen identified multiple regeneration-restricting genes and used CRISPR validation to define target candidates for regulatory repression. | CRISPR-validated regeneration suppressor targets | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Comparator; not epigenome editing efficacy. |
| M14B-O010 | M14B-T006 | M14A-P010 | M14A-P010-E001 | Full-text PMC | regeneration target-discovery evidence | KLF4-linked axon growth regulation | miRNA-135/KLF4 work supports KLF4-family repression as an intrinsic-growth target logic relevant to CRISPRi. | KLF4 repression target logic | qualitative | NO | Full-text first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Target-discovery comparator. |
| M14B-O011 | M14B-T003 | M14A-P011 | M14A-P011-E001 | Abstract/source page | epigenome editing tool evidence | promoter/enhancer acetylation | dCas9-p300 provides a programmable enhancer/promoter acetylation strategy relevant to activating regeneration-associated loci. | dCas9-p300 acetylation activation tool | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Activation effector boundary. |
| M14B-O012 | M14B-T003 | M14A-P012 | M14A-P012-E001 | Abstract/source page | CRISPR transcriptional regulation evidence | activation/repression without DNA cleavage | Foundational CRISPRi/a work establishes guide-programmable transcriptional regulation without DNA cleavage. | guide-programmable transcriptional regulation | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Foundational tool boundary. |
| M14B-O013 | M14B-T003 | M14A-P013 | M14A-P013-E001 | Abstract/source page | CRISPRa platform evidence | multiplexed activation and screening | SAM CRISPRa establishes multiplexed activation logic for discovering growth-promoting regulatory programs. | multiplexed CRISPRa target discovery | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | CRISPRa discovery boundary. |
| M14B-O014 | M14B-T007 | M14A-P014 | M14A-P014-E001 | Abstract/source page | in vivo CNS CRISPRa evidence | therapeutic-style endogenous activation | In vivo CNS CRISPRa proof-of-concept supports therapeutic feasibility boundaries for gene activation in neural tissue. | in vivo CNS CRISPRa feasibility | qualitative | NO | Source-page first pass | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Translation comparator. |
| M14B-O015 | M14B-T007 | M14A-P015 | M14A-P015-E001 | Full-text PMC | nervous-system CRISPR review evidence | delivery and safety boundary | Nervous-system CRISPR review provides delivery, specificity, and tool-class boundaries for CNS translation. | CNS CRISPR delivery and safety boundaries | qualitative | NO | Review-level evidence | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Safety/tool-class boundary. |
| M14B-O016 | M14B-T008 | M14A-P016 | M14A-P016-E001 | Full-text PMC | neuroregeneration review evidence | reversible growth-program regulation | Recent review frames epigenetic CRISPR editing as reversible/flexible gene-program control for neuroregeneration, while requiring validation before clinical claims. | epigenetic CRISPR as flexible neuroregeneration platform | qualitative | NO | Review-level evidence | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Project-level translation boundary. |

## Pass 5A: Author Claims Extracted

| Claim ID | Topic ID | Paper ID | Claim Text | Claim Type | Confidence Level | Source Section | Extraction Confidence | Notes |
|---|---|---|---|---|---|---|---|---|
| M14B-C001 | M14B-T001 | M14A-P001 | CRISPR/dCas9-KRAB repression of PTEN is a direct regeneration-relevant epigenome-editing strategy because it modifies promoter chromatin and improves neurite outgrowth in neural cells. | mechanistic | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Full-text quantitative upgrade queued. |
| M14B-C002 | M14B-T002 | M14A-P002 | Neuron-optimized CRISPRa can activate endogenous neuronal genes in a tunable, multiplexed, promoter-selective manner in vitro and in vivo. | tool validation | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Tool-platform claim. |
| M14B-C003 | M14B-T003 | M14A-P003 | Neuroepigenome editing requires effector-specific interpretation because CRISPRa, CRISPRi, DNMT, TET1, p300, and histone-modifying systems produce different regulatory states. | boundary condition | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Review-level claim. |
| M14B-C004 | M14B-T002 | M14A-P004 | dCas9 expands CNS CRISPR from permanent editing into modular local chromatin and gene-regulatory perturbation. | tool validation | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | CNS tool claim. |
| M14B-C005 | M14B-T003 | M14A-P005 | Enhancer activation/repression and epigenome manipulation should be separated from nuclease-based genome editing in neurobiology. | boundary condition | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Tool-class boundary. |
| M14B-C006 | M14B-T004 | M14A-P006 | SCI epigenetic landmarks are relevant target-selection evidence for axon regeneration, glial activation, neurogenesis, and secondary injury. | synthesis | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | SCI context claim. |
| M14B-C007 | M14B-T004 | M14A-P007 | Injury-responsive enhancer regulation can nominate regeneration-associated loci that may later be tested with CRISPR epigenome editing. | target nomination | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Enhancer target claim. |
| M14B-C008 | M14B-T005 | M14A-P008 | Injury-responsive enhancers provide a route to cell-state-specific targeting in injured CNS tissue, including reactive astrocyte states after spinal cord injury. | tool validation | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Source-page confidence retained. |
| M14B-C009 | M14B-T006 | M14A-P009 | CRISPR-validated regeneration screens nominate target genes for regulatory repression but do not prove dCas9 epigenome-editing efficacy by themselves. | boundary condition | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Comparator boundary. |
| M14B-C010 | M14B-T006 | M14A-P010 | KLF-family repression is a credible intrinsic-growth target logic for CRISPRi-style neuroregeneration experiments. | target nomination | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Comparator target evidence. |
| M14B-C011 | M14B-T003 | M14A-P011 | dCas9-p300 supports a promoter/enhancer acetylation strategy for activating silent or insufficiently active growth-associated loci. | tool validation | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Activation effector claim. |
| M14B-C012 | M14B-T003 | M14A-P012 | CRISPRi/a establishes programmable transcriptional control without DNA cleavage, which is the core distinction from permanent genome editing. | tool validation | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Foundational tool claim. |
| M14B-C013 | M14B-T003 | M14A-P013 | Multiplexed CRISPRa can be used as a discovery strategy for coordinated pro-regenerative gene programs. | tool validation | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Platform claim. |
| M14B-C014 | M14B-T007 | M14A-P014 | In vivo CNS CRISPRa examples support feasibility of endogenous gene activation in neural tissue but remain disease/model-specific. | boundary condition | medium | Module 14A tracker / source-page, full-text PMC, or review metadata | medium | Translation comparator. |
| M14B-C015 | M14B-T007 | M14A-P015 | CNS CRISPR translation requires delivery, specificity, immune/off-target, durability, and tool-class safety boundaries. | boundary condition | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Safety boundary. |
| M14B-C016 | M14B-T008 | M14A-P016 | CRISPR epigenome editing is best framed as a reversible/flexible neuroregeneration platform until direct in vivo SCI efficacy and safety are shown. | synthesis | high | Module 14A tracker / source-page, full-text PMC, or review metadata | high | Project-level boundary. |

## Pass 6: Evidence Links Drafted

| Evidence Link ID | Claim ID | Observation ID | Link Type | Strength | Notes |
|---|---|---|---|---|---|
| M14B-L001 | M14B-C001 | M14B-O001 | supports | medium | Direct first-pass link from PTEN dCas9-KRAB claim to observation. |
| M14B-L002 | M14B-C002 | M14B-O002 | supports | high | Direct first-pass link from neuronal CRISPRa claim to observation. |
| M14B-L003 | M14B-C003 | M14B-O003 | supports | medium | Direct first-pass link preserving review-level confidence. |
| M14B-L004 | M14B-C004 | M14B-O004 | supports | high | Direct first-pass link preserving full-text review confidence. |
| M14B-L005 | M14B-C005 | M14B-O005 | supports | high | Direct first-pass link preserving full-text review confidence. |
| M14B-L006 | M14B-C006 | M14B-O006 | supports | high | Direct first-pass link preserving SCI epigenetic context. |
| M14B-L007 | M14B-C007 | M14B-O007 | supports | high | Direct first-pass link from enhancer claim to observation. |
| M14B-L008 | M14B-C008 | M14B-O008 | supports | medium | Direct first-pass link preserving source-page confidence. |
| M14B-L009 | M14B-C009 | M14B-O009 | supports | medium | Direct first-pass comparator link. |
| M14B-L010 | M14B-C010 | M14B-O010 | supports | high | Direct first-pass KLF4 target link. |
| M14B-L011 | M14B-C011 | M14B-O011 | supports | medium | Direct first-pass p300 tool link. |
| M14B-L012 | M14B-C012 | M14B-O012 | supports | medium | Direct first-pass CRISPRi/a platform link. |
| M14B-L013 | M14B-C013 | M14B-O013 | supports | medium | Direct first-pass SAM CRISPRa link. |
| M14B-L014 | M14B-C014 | M14B-O014 | supports | medium | Direct first-pass in vivo CNS CRISPRa comparator link. |
| M14B-L015 | M14B-C015 | M14B-O015 | supports | high | Direct first-pass CNS safety boundary link. |
| M14B-L016 | M14B-C016 | M14B-O016 | supports | high | Direct first-pass neuroregeneration synthesis link. |
| M14B-L017 | M14B-C001 | M14B-O009 | contextual_support | low | Target-discovery comparator supports repression-target logic but not dCas9 efficacy. |
| M14B-L018 | M14B-C001 | M14B-O010 | contextual_support | low | KLF4 repression comparator supports intrinsic-growth target boundary. |
| M14B-L019 | M14B-C002 | M14B-O004 | contextual_support | low | CNS CRISPR review supports neuronal tool context. |
| M14B-L020 | M14B-C002 | M14B-O014 | contextual_support | low | In vivo CNS CRISPRa comparator supports translation boundary. |
| M14B-L021 | M14B-C003 | M14B-O011 | contextual_support | low | p300 tool row supports effector-specific activation boundary. |
| M14B-L022 | M14B-C003 | M14B-O012 | contextual_support | low | Foundational CRISPRi/a row supports activation/repression distinction. |
| M14B-L023 | M14B-C003 | M14B-O013 | contextual_support | low | SAM platform supports multiplexed activation boundary. |
| M14B-L024 | M14B-C004 | M14B-O002 | contextual_support | low | Neuron-optimized CRISPRa row supports CNS dCas9 platform claim. |
| M14B-L025 | M14B-C005 | M14B-O003 | contextual_support | low | Neuroepigenome review supports tool-class distinction. |
| M14B-L026 | M14B-C006 | M14B-O007 | contextual_support | low | WNT3A enhancer row supports SCI epigenetic target logic. |
| M14B-L027 | M14B-C006 | M14B-O008 | contextual_support | low | SCI injury enhancer row supports cell-state target logic. |
| M14B-L028 | M14B-C007 | M14B-O011 | contextual_support | low | dCas9-p300 row supports possible enhancer activation strategy. |
| M14B-L029 | M14B-C008 | M14B-O015 | contextual_support | low | CNS CRISPR safety review contextualizes delivery boundary. |
| M14B-L030 | M14B-C009 | M14B-O001 | contextual_support | low | PTEN dCas9 row distinguishes direct epigenome editing from target discovery. |
| M14B-L031 | M14B-C010 | M14B-O009 | contextual_support | low | Optic nerve screen supports target-discovery comparator logic. |
| M14B-L032 | M14B-C011 | M14B-O007 | contextual_support | low | WNT3A enhancer row contextualizes acetylation target logic. |
| M14B-L033 | M14B-C012 | M14B-O003 | contextual_support | low | Neuroepigenome review supports non-cleaving regulatory edit boundary. |
| M14B-L034 | M14B-C013 | M14B-O002 | contextual_support | low | Neuronal CRISPRa row contextualizes multiplexed neuronal activation. |
| M14B-L035 | M14B-C014 | M14B-O002 | contextual_support | low | Neuronal CRISPRa platform supports in vivo CNS feasibility logic. |
| M14B-L036 | M14B-C015 | M14B-O003 | contextual_support | low | Neuroepigenome editing review contextualizes safety/durability concerns. |
| M14B-L037 | M14B-C015 | M14B-O014 | contextual_support | low | In vivo CNS CRISPRa example contextualizes delivery boundary. |
| M14B-L038 | M14B-C016 | M14B-O001 | contextual_support | low | Direct PTEN row supports platform but remains in vitro. |
| M14B-L039 | M14B-C016 | M14B-O008 | contextual_support | low | Injury enhancer row supports cell-state-targeted platform logic. |
| M14B-L040 | M14B-C016 | M14B-O015 | contextual_support | low | CNS CRISPR review supports safety boundary for project-level claim. |

## Boundary Conditions Draft

| Boundary ID | Boundary Statement | Observation IDs | Claim IDs | Status |
|---|---|---|---|---|
| M14B-B001 | CRISPR epigenome editing must be separated from nuclease-active knockout, base editing, and prime editing unless those tools are used only as target-discovery comparators. | M14B-O001-O016 | M14B-C001-C016 | ACTIVE |
| M14B-B002 | Effector domain matters: KRAB repression, VP64/VPR/SAM activation, p300 acetylation, TET1 demethylation, and DNMT methylation should not be pooled as one mechanism. | M14B-O001-O013 | M14B-C001-C013 | ACTIVE |
| M14B-B003 | Direct neuroregeneration evidence is currently strongest for in vitro PTEN repression; target-discovery rows cannot substitute for direct dCas9 epigenome-editing efficacy. | M14B-O001-O010 | M14B-C001-C010 | ACTIVE |
| M14B-B004 | Neuronal, astrocytic, oligodendroglial, macrophage/microglial, and graft-cell targets require separate delivery and endpoint boundaries. | M14B-O002-O008 | M14B-C002-C008 | ACTIVE |
| M14B-B005 | Injury-responsive enhancer evidence can guide targeting and regulatory design but does not by itself prove repair efficacy. | M14B-O007-O008 | M14B-C007-C008 | ACTIVE |
| M14B-B006 | CNS translation requires vector-capacity, expression-duration, immune-response, off-target regulation, and reversibility/durability fields. | M14B-O003-O016 | M14B-C003-C016 | ACTIVE |
| M14B-B007 | SCI reconstruction claims must specify whether the edit targets intrinsic axon growth, glial/immune host state, lesion remodeling, graft integration, or biomaterial response. | M14B-O001-O016 | M14B-C001-C016 | ACTIVE |
| M14B-B008 | Consensus statements should frame CRISPR epigenome editing as a programmable discovery and validation platform until in vivo SCI regeneration and safety evidence matures. | M14B-O001-O016 | M14B-C001-C016 | ACTIVE |

## Consensus Draft Queue

| Consensus ID | Topic ID | Draft Statement | Supporting Observations | Supporting Claims | Boundary Records | Status | Notes |
|---|---|---|---|---|---|---|---|
| M14B-S001 | M14B-T001 | CRISPR/dCas9 epigenome editing is consensus-ready as a regeneration-relevant regulatory strategy because dCas9-KRAB can repress PTEN in neural cells, induce local repressive chromatin marks, and improve neurite outgrowth; however, this direct evidence is still primarily in vitro and should not be overstated as in vivo SCI efficacy. | M14B-O001-O003 | M14B-C001-C003 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S002 | M14B-T002 | Neuron-optimized CRISPRa/i systems provide a practical platform for tunable endogenous gene regulation in post-mitotic neural cells, including promoter-selective and multiplexed activation, but each claim must preserve vector, cell type, guide, expression, and in vivo/in vitro boundaries. | M14B-O002-O004 | M14B-C002-C004 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S003 | M14B-T003 | CRISPR epigenome editing should be organized by effector mechanism rather than by the word CRISPR alone: repression, activation, acetylation, methylation, demethylation, and scaffolded activator systems produce different chromatin states, durations, and safety questions. | M14B-O003-O005 | M14B-C003-C005 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S004 | M14B-T004 | SCI and CNS injury epigenetic maps are useful for nominating regulatory targets because injury changes chromatin, enhancer activity, glial activation, neurogenesis, and axon-growth programs, but map evidence must be followed by perturbation before causal repair claims. | M14B-O006-O008 | M14B-C006-C008 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S005 | M14B-T005 | Injury-responsive enhancers create an important bridge between epigenome editing and cell-state specificity: they may help target reactive CNS states such as astrocytes after SCI, but enhancer targeting is a delivery/regulatory specificity claim until linked to repair endpoints. | M14B-O007-O008 | M14B-C007-C008 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S006 | M14B-T006 | Neuroregeneration screens and intrinsic-growth target studies identify candidate loci for CRISPRi/a, including PTEN/KLF-style repression and regeneration-associated gene activation, but target discovery is not equivalent to dCas9 epigenome-editing efficacy. | M14B-O009-O010 | M14B-C009-C010 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S007 | M14B-T007 | CNS delivery and safety are central boundaries for CRISPR epigenome editing: vector capacity, cell specificity, immune response, off-target regulation, expression duration, reversibility, and durability must be recorded before translational neuroregeneration claims. | M14B-O011-O015 | M14B-C011-C015 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |
| M14B-S008 | M14B-T008 | Module 14 should be used as a programmable regulatory-editing layer for neuroregeneration: candidate experiments should specify target locus, effector, guide design, delivery vehicle, target cell, chromatin state, model, and endpoint before linking CRISPR epigenome editing to SCI reconstruction, conditioning, graft integration, or axon repair. | M14B-O014-O016 | M14B-C014-C016 | M14B-B001-B008 | CONSENSUS-READY FIRST PASS | Module 14 first-pass curation freeze. |

## Readiness Checklist

| Check | Status | Notes |
|---|---|---|
| Module 14A corpus saturated | MET FOR ALL FIRST-PASS TOPICS | 16 source rows cover direct PTEN evidence, neuronal CRISPRa, chromatin-effectors, injury enhancers, target discovery, SCI epigenetic context, and safety. |
| Experiment-level rows extracted | MET FOR ALL FIRST-PASS TOPICS | One bounded experiment row per first-pass source row. |
| Atomic observations separated from claims | MET FOR ALL FIRST-PASS TOPICS | Observations preserve empirical source-page/full-text/review confidence. |
| Claims linked to observations | MET FOR ALL FIRST-PASS TOPICS | 40 evidence links drafted. |
| Contradictions and boundaries recorded | MET FOR ALL FIRST-PASS TOPICS | Tool class, effector, target, cell type, delivery, endpoint, and translation boundaries recorded. |
| Consensus statements drafted | CONSENSUS-READY FIRST PASS | Eight consensus-ready statements drafted from linked observations and claims. |

## First-Pass Decision

| Decision ID | Status | Basis | Boundary / Queue |
|---|---|---|---|
| M14B-D001 | CONSENSUS-READY FIRST PASS | 16 observations, 16 author claims, 40 evidence links, 8 boundary records, and 8 consensus-ready statements extracted from the saturated Module 14A corpus. | Export tracker evidence bundle, full SQL materialization, consensus review register, and cross-module synthesis after wiring Module 14 into the scripts. |
